Silent subtype III pituitary adenomas (SS-3) are clinically nonfunctional adenomas that are more aggressive in terms of invasion and risk of recurrence than their conventional null cell counterparts. We previously showed that these tumors can be distinguished by immunohistochemistry based on the identification of a markedly enlarged and fragmented Golgi apparatus. To understand the molecular correlates of differential aggressiveness, we performed whole transcriptome sequencing (RNAseq) on 4 SS-3 and 4 conventional null cell adenomas. The genes that were highly upregulated in all the SS-3 adenomas included 2 secreted proteins involved in the suppression of T-lymphocyte activity, i.e., ARG2 (multiple testing adjusted p adj ¼ 1.5 Â 10 À3 ) and SEMA3A (p adj ¼ 3.3 Â 10 À3 ). Highly downregulated genes in all the SS-3 adenomas included HLA-B (p adj ¼ 3.3 Â 10 À6 ), suggesting reduced antigen presentation by the adenoma to cytotoxic T-cells. Quantitative RT-PCR of these genes performed on the adenoma samples supported the RNAseq results. We also found a relative decrease in the overall concentration of T-lymphocytes in the SS-3 tumors. These results suggest that SS-3 adenomas actively suppress the immune system and raise the possibility that they may be treatable with immune checkpoint inhibitors or nonspecific cancer immunotherapies.
INTRODUCTION
First identified and characterized ultrastructurally in the 1980's, silent subtype III pituitary adenomas (SS-3) account for <2% of all pituitary adenomas (1, 2) . It has recently been suggested that these tumors represent a poorly differentiated member of the Pit-1 family of pituitary adenomas, which includes growth hormone (GH)-, thyroid stimulating hormone (TSH)-, and prolactin (PRL)-secreting adenomas (3) . These SS-3 adenomas have been shown to be significantly more aggressive than their more indolent null cell (NC) counterparts in terms of frequency of recurrence and invasion into bone or into the surrounding cavernous sinus (2, (4) (5) (6) (7) (8) . Classically, SS-3 was differentiated from conventional null cell adenomas only by electron microscopy findings, most importantly an enlarged and multicentric Golgi apparatus, similar to that seen in hormone-producing adenomas, in the setting of a nonfunctional adenoma (1, 2, 5) . We have recently shown that the diagnosis can be made by visualizing the enlarged and tortuous Golgi apparatus with an immunohistochemical stain specific to the Golgi apparatus, GLG-1/MG-160 (4). The enlarged Golgi apparatus raises the possibility that these tumor cells are producing a yet unknown secreted gene product that could potentially be contributing to the increased aggressive behavior attributed to SS-3 adenomas or be used as a biomarker for diagnosis and/or prognosis.
We evaluated a small cohort of SS-3 adenomas compared them to a group of conventional null cell adenomas by whole-transcriptome sequencing to search for upregulated or downregulated gene products, focusing on cancer-related proteins and secreted proteins. In this study, the SS-3 pituitary adenomas showed a marked increase of the level of mRNA of secreted gene products linked to immunosuppression and Tcell regulation including ARG2 and SEMA3A, as well as a marked decrease of HLA-B expression relative to a conventional null cell pituitary adenoma control group. The alterations in the expression of all 3 of these genes have been linked to worse outcomes in other types of tumors (9) (10) (11) (12) (13) (14) . These data could partially explain the increased aggressiveness seen with the SS-3 subtype as well as provide additional therapeutic options targeting these immunomodulatory proteins (2, 4, 5) .
MATERIALS AND METHODS

Case Selection and Clinical Review
We identified 4 cases with the diagnosis silent subtype III pituitary adenoma using a SNOMED database search at our institution. This diagnosis had been made at the time of the original neuropathologic work-up from 2013 to 2015 primarily based on the clinical impression of a nonsecreting pituitary tumor combined with the pathology finding of a markedly enlarged Golgi apparatus, as identified by GLG-1/MG-160 immunohistochemistry in the absence of any significant immunoreactivity to pituitary hormones, according to our previously published method (4) (Supplementary Data Fig.  S1 ). In addition, we randomly selected 4 cases with the diagnosis of "null cell adenoma," from 2013 to 2015. All available clinical history, physical examination findings, imaging results, laboratory results, operative reports, pathology findings, and subsequent follow-up encounters were reviewed and relevant data are reported in Table 1 . The study was performed in accordance with a protocol approved by the Institutional Review Board of the University of Texas Southwestern Medical Center (IRB STU 022011-081).
Immunohistochemistry
Four-mm-thick sections of formalin-fixed paraffin-embedded (FFPE) tissue underwent heat-induced epitope retrieval using CC1 (Ventana Medical Systems, Inc., Tucson, AZ), a tris-based buffer at an 8-8.5 pH followed by immunohistochemical staining with the polyclonal rabbit antibody antiMG-160 (GLG-1) (Sigma Life Science Prestige Antibodies, St. Louis, MO), on either the Ventana Benchmark XT or Ventana Benchmark Ultra automated stainer, using Ventana UltraView Universal DAB Detection Kit. Similar immunostaining was also performed using mouse monoclonal antisynaptophysin (Ventana), rabbit polyclonal antiPRL (Ventana), rabbit polyclonal antiadrenocorticotrophic hormone ([ACTH] Ventana), rabbit polyclonal antiGH (Ventana), mouse monoclonal antiTSH (Dako North America, Inc., Carpinteria, CA), mouse monoclonal antifollicle stimulating hormone (Ventana), mouse monoclonal antiluteinizing hormone (Dako), mouse monoclonal antiKi-67 (Dako), and rabbit monoclonal antiCD3 (Ventana) antibodies. The Ki-67/MIB-1 labeling indices were quantified using a Glasgow cell counting graticule at 400Â magnification (15).
RNA Purification From Paraffin Sections
Formalin-fixed, paraffin-embedded tissue blocks were sectioned at a thickness of 10 mm. Freshly cut sections were placed in 2 mL microcentrifuge tubes and deparaffinized by vortexing in xylene, followed by centrifugation. ) and manufacturers recommended protocol. One hundred pM of pooled libraries were combined and 25 ml of each sample was loaded onto the Ion Chef. The Ion Chef templates, enriches, and loads the sample onto a P1 chip, and then after 15 hours the Chef pauses so that QC can be performed on the unenriched samples. After the pause, the beads were isolated and quality assessment was performed on Qubid instrument to determine the percent of beads that were polyclonal. After polyclonal assessment, the Ion Chef resumed running and loaded the samples onto a P1 chip. The loaded chip was then placed into an Ion Proton sequencer and the run was started using an Ion torrent Ampliseq transcriptome run plan that was configured based on type of library, species, number of run flows required, type of plug-in required, adapter-trimming as well as other parameters specific to the Ampliseq transcriptome run. Alignment and Data Analysis: Fastq files were checked for quality using fastqc v0.11.2 (http://www.bioinformatics. babraham.ac.uk/projects/fastqc) and fastq screen v0.4.4 (http://www.bioinformatics.babraham.ac.uk/projects/fastq_ screen) and were quality trimmed using fastq-mcf (ea-utils/ 1.1.2-806) (16) . Trimmed fastq files were mapped to hg19 (UCSC version from iGenomes) using TopHat (17); duplicates were marked using picard-tools (v1.127 https:// broadinstitute.github.io/picard/); read counts were generated using featureCounts (18) ; and differential expression analysis was performed using edgeR (19) . Differentially expressed gene heat maps were clustered by hierarchical clustering using R (http://www.R-project.org) (Fig. 1 ).
Quantitative RT-PCR Confirmation of Whole Transcriptome Sequencing Results
RNA was purified from two 10-lm FFPE sections from each case as described above. cDNA Quantitative PCR was performed with a SYBR PCR master mix with the primers purchased from OriGene Technologies, Inc. (Rockville, MD). 
Pathway Analysis
All genes with significant differential expression between SS-3 and NC groups (p adj 0.05; n ¼ 213 genes) were used for pathway analysis with QIAGEN's Ingenuity Pathway Analysis tool (QIAGEN, http://www.qiagen.com/ingenuity). The resulting full list of the 287 enriched canonical pathways along with the p-values, gene ratios, Z-scores, and pathway component molecules are reported in Supplementary Data Table S1 .
Relative Quantification of Lymphocytes
The relative extents of tumor infiltrating lymphocytes (TILs) were determined by visual inspection of 5 randomly selected areas of 1 antiCD3-stained section of each case from this study, as well as 10 null cell and 10 silent subtype III cases from our previous study (4) . The following approximate grades were designated: À (completely absent); þ (rare TILs or lymphocytes restricted to adjacent tissue); þþ (widespread lymphocytes infiltrating into 5%-25% of the area of the tumor); and þþþ (lymphocytes infiltrating into !25% of the tumor) (22) .
Statistics
For RNAseq data, false discovery rate (FDR) control procedure was performed, and the adjusted p values (p adj ) <0.05 were considered significant. For TIL analysis, nonparametric Mann-Whitney U-testing was performed (http://vassar stats.net).
RESULTS
Clinical and Pathological Features
As previously reported, the SS-3 pituitary adenomas generally had more invasive characteristics than the conventional null cell adenomas (4) . While none of the null cell cases were invasive according to the previously established definition of invasion (8), 3 of the SS-3 tumors included herein invaded into the cavernous sinuses with !50% encasement of at least 1 cavernous internal carotid artery. In addition, while no NC tumor showed evidence of recurrence, 2 of the SS-3 tumors subsequently recurred; and 1 patient had undergone 3 previous resections for similar pituitary adenomas before being seen at our institution. There was a significant difference in the MIB-1 proliferative index between these 2 groups with the NC group measuring 0.83% 6 0.36% and the SS-3 group measuring 2.68% 6 0.59% (p ¼ 0.0017). No significant difference was noted in the patient age, 61.8 6 12.5 years and 47.3 6 17.4 years in the NC and SS-3 groups, respectively (p ¼ 0.22). Similarly, there was no difference in tumor size between the 2 groups, (2.93 6 1.98 cm and 3.68 6 2.21 cm in greatest dimension in the NC and SS-3 groups, respectively, p ¼ 0.63).
Altered Expression of Genes Related to Immune Surveillance Mechanisms in SS-3 Pituitary Adenomas
Compared with the conventional null cell pituitary adenoma group, SS-3 adenomas had significantly increased levels of ARG2 (17.5-fold increase; p adj ¼ 1.5 Â 10
À3
) and SEMA3A (64.6-fold increase; p adj ¼ 3.3 Â 10
) mRNA, as well as significantly decreased levels of HLA-B (212-fold decrease; p adj ¼ 3.3 Â 10
À6
; all p-values adjusted for multi-hypothesis testing) (Fig. 2) . Of all genes identified by this method, these genes are among the most statistically significant and among those with the greatest fold changes (Fig. 3) . These data are consistent with observations in other tumor types where similar changes have been linked with decreased T-cell proliferation and infiltration, increased tumor growth, increased lymph node and distant organ metastases, and decreased response to therapy. The results for the 3 genes were confirmed by qRT-PCR analysis, normalized to b-actin mRNA levels in each sample (p < 0.01).
Other Differences in Whole-Transcriptome Sequencing mRNA Levels
Whole transcriptome differential expression analysis demonstrated the following additional genes differentially expressed at the FDR level of 0.05: a 95.6-fold increase in GHRHR, a 60.4-fold increase in HEPACAM2, a 64.9-fold increase in GHSR, a 59.3-fold increase in GADD45G, a 33.2-fold increase in NNAT, and a 25.7-fold increase in MET (Fig. 1 ). In addition, there was a 55.6-fold decrease in LGI1, a 32.3-fold decrease in BMP5, an 18.5-fold decrease in Emilin2, a 13.9-fold decrease in PIK3C2G, a 11.3-fold decrease in DIRC3, a 10.7-fold decrease in HLA-DRB1 (Fig. 3) , and a 5.2-fold decrease in TAGLN.
Pathway Analysis
The pathway analysis suggests that several canonical signaling pathways known to be associated with cellular proliferation, T-lymphocyte regulation and inhibition, as well as angiogenesis in various cancers are also activated in aggressive pituitary adenomas such as SS-3 adenomas (Table 2) .
Decreased Numbers of CD3-Positive Lymphocytes in SS-3 Tumors
We evaluated the numbers of CD3-positive TILs in cases 1-8, as well as an additional 10 NC cases and 10 SS-3 cases from our previous cohort (4) . All NC and the majority of SS-3 cases had some lymphocytes in the tumor and in the tissue surrounding the tumor, which suggests that the adenomas can elicit a T-cell response. The SS-3 cases had absent to rare T-cells sparsely scattered through the tissue, while there were variably increased T-cell numbers in the null cell tumors (Fig. 4 ; Table 3 ). There was a significant difference between the SS-3 and NC groups in terms of TIL numbers by Mann-Whitney 
DISCUSSION
Having previously confirmed the significantly worse prognosis associated with SS-3 adenomas compared with conventional null cell adenomas (4), we performed RNAseq on a subset of our SS-3 adenoma cases to identify genes that could potentially explain this difference in outcome. RNAseq demonstrated a clear difference in overall RNA expression profiles between the 2 tumor types (Fig. 1) and identified a number of genes that could be involved with aggressive behavior in SS-3 adenomas. Notably, ARG2 and SEMA3A, both of which are involved in the regulation of T-cell proliferation and function within the tumor microenvironment (9, 11, 12, 14, (23) (24) (25) , were markedly increased in all of the SS-3 adenomas (Figs. 2  and 3 ). These genes and others identified by our analysis are involved in a number of altered genetic pathways including cellular proliferation, angiogenesis, and local T-cell immune response regulation in other cancers (Table 2) . Because drugs targeting the components of these pathways are already available or in clinical trials, our results raise the possibility that these drugs may prove to be effective in some patients with invasive SS-3 adenomas. It should be kept in mind that this type of canonical pathway analysis does not necessarily detect all relevant signaling pathways, and genetic and epigenetic alterations such as the methylation profile at the genomic level would not be captured by this pathway analysis. In addition, subsequent immunohistochemical staining for CD3 demonstrated a smaller number of tumor infiltrating lymphocytes in the SS-3 group versus the NC group ( Fig. 4; Table 3 ), which may reflect the differential expression of T-cell influencing genes.
Methods by which tumor cells escape from or actively suppress immune surveillance are active areas of investigation (26) . This process has been divided into 3 phases: elimination, in which the immune system is able to recognize and eliminate tumor or pretumor cells; equilibrium, in which the immune system is able to prevent the tumor from growing or metastasizing; and escape, in which the tumor cells have developed mechanisms for evading the immune system and the tumor is able to expand (27, 28) . A variety of different genes have been implicated in the modulation of the tumor microenvironment and subsequent escape from T-cell mediated immunosurveillance in a variety of different tumors, including melanoma, multiple myeloma, neuroblastoma, prostate cancer, breast cancer, and various sarcomas (23, 25, 26, 29, 30) .
Recently, the secreted molecule arginase-II (ARG2), which converts L-arginine to L-ornithine and urea in the final step of the urea cycle (31), has been implicated in the inhibition of immune surveillance. It has been shown that high concentrations of ARG2 are often present both systemically and in the tumor microenvironment of various cancer types, resulting in reduction of arginine and suppression of T-cell function. Therefore, ARG2 is a plausible therapeutic target, and, indeed, arginase inhibitors have already been used clinically for other conditions (25, 30) .
Similarly, the gene product of SEMA3A, semaphorin 3 A (SEMA3A), has a potential local immunosuppressive function in neoplastic conditions. Secreted under normal conditions by T-cells as part of a negative feedback loop and aberrantly by some tumor cells, SEMA3A acts on neuropilin-1 (NP-1) to suppress T-cell proliferation and function, a process that has been positively correlated with tumor invasion and metastasis (14) . Studies have demonstrated that this SEMA3A-NP-1 interaction blocks cytoskeleton reorganization in T-cells and inhibits T-cell receptor signaling in vivo, and that the inhibition of SEMA3A significantly restores T-cell proliferation in vitro (12) .
HLA class I proteins, including HLA-B, are expressed on all nucleated cells to present antigen to circulating cytotoxic T-cells (10, 13) . Many types of cancer cells have been demonstrated to selectively downregulate HLA proteins (effectively hiding tumor antigens from cytotoxic T-cells) as a strategy to avoid immune system detection (10, 13, (32) (33) (34) (35) (36) . Multiple studies have shown that downregulation or loss of HLA signaling proteins on the cell surface of tumor cells is associated with a significantly worse outcome in a wide variety of cancer types (10, 33, 37) .
By depleting the local environment of arginine needed for T-cell function and preventing T-cell proliferation and signaling through interaction with NP-1, respectively, ARG2 and SEMA3A act to inhibit the function of adjacent T-cells. By downregulating HLA-B, the tumor cells may also be able to avoid detection by any cytotoxic T-cells present (10, 13) . The altered levels of these 3 gene products may act synergistically at multiple levels of the cell mediated immune response to suppress the proliferation, metabolic activity, and function of T-cells, allowing the tumor to escape the immune surveillance pathway and grow unchecked in a manner unavailable to conventional null cell adenomas (27, 28, 38) . Our qualitative finding that there is a generalized decrease in infiltrating T-cells in the SS-3 group seems to support the hypothesis that the altered mRNA levels of ARG2, SEMA3A, and HLA-B may act to inhibit T-cell presence and activity within these tumors. ARG2 and SEMA3A are potentially targetable molecules, as inhibitors are currently being investigated in in vivo and in vitro studies (12, 30) and could allow for normalization of T-cell proliferation and activity. This study is also a further validation of our previously described method for differentiating SS-3 adenomas from conventional null cell adenomas using GLG-1 immunohistochemistry (4) (Supplementary Data Fig. S1 ), as it demonstrates that there is indeed a qualitative and quantitative difference in mRNA expression patterns between these 2 tumor types Figs. 1-3 ) and suggests a potential mechanism for increased aggressiveness in the SS-3 cohort. However, it is unclear if the increased production of these mRNA species in SS-3 compared with NC adenomas fully explains the enlargement and fragmentation of the Golgi apparatus in SS-3 adenomas.
In conclusion, this RNA analysis suggests a potentially targetable mechanism for the previously observed aggressive behavior of SS-3 adenomas (2, 4, 5) . By downregulating the expression of antigen-presenting molecules and upregulating the expression of secreted proteins that inhibit the metabolism, function, and proliferation of local cytotoxic T-cells, these tumors can escape from immune surveillance and thus may grow more rapidly and recur more frequently.
